Cervical Cancer | Topics

 
Cancer Vaccine VB10.16 Plus Atezolizumab Yields Promising Responses in HPV16+ Advanced Cervical Cancer
May 10, 2022

Patients with advanced human papillomavirus 16–positive cervical cancer appear to benefit from treatment with VB10.16 and atezolizumab.

European Commission Approves Pembrolizumab Plus Chemotherapy With or Without Bevacizumab for Cervical Cancer
May 03, 2022

Patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 can receive treatment with pembrolizumab plus chemotherapy with or without bevacizumab following approval by the European Commission.

Jyoti S. Mayadev, MD, on Atezolizumab for Locally Advanced, Node-Positive Cervical Cancer
April 07, 2022

At SGO 2022, Jyoti S. Mayadev, MD presented results of the NRG-GY017 trial of atezolizumab as either an immune primer or with chemoradiation for certain patients with locally advanced cervical cancer.

Jyoti Mayadev, MD, Provides Perspective on Atezolizumab in Locally Advanced Cervical Cancer
March 28, 2022

At SGO 2022, CancerNetwork® spoke with Jyoti Mayadev, MD, about a clinical trial involving immune priming with the PD-L1 inhibitor atezolizumab for patients with locally advanced cervical cancer.

Addition of Durvalumab to CRT Did Not Significantly Improve PFS vs CRT Alone in Locally Advanced Cervical Cancer
March 25, 2022

Patients with locally advanced cervical cancer did not see further benefit from the addition of concurrent durvalumab to chemoradiotherapy.

T-Cell Clonal Expansion Achieved by Adding Atezolizumab to Chemoradiation for Locally Advanced Cervical Cancer
March 19, 2022

Results of the phase 1 NRG-GY017 trial show promise of atezolizumab as an immune primer in locally advanced cervical cancer.

Patient-Reported Outcomes Provide Additional Support for Pembrolizumab Combo in First-Line Cervical Cancer
March 19, 2022

Updated results from the KEYNOTE-826 study show a favorable risk-benefit ratio for pembrolizumab plus chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer.

Clinical Trial for Patients With Previously Treated Recurrent or Metastatic Cervical Cancer Is Exploring Ociperlimab Plus Tislelizumab Combo
March 19, 2022

An anti-TIGIT/anti–PD-1 combination approach with ociperlimab plus tislelizumab will be examined in a phase 2 study of patients with previously treated recurrent or metastatic cervical cancer.

Cemiplimab Achieves Promising Survival in Recurrent Cervical Cancer
February 14, 2022

Patients with recurrent cervical cancer appeared to achieve a promising survival benefit following treatment with cemiplimab.

Pembrolizumab Prolongs Survival Over Placebo for Persistent, Recurrent, or Metastatic Cervical Cancer
February 09, 2022

Pembrolizumab for patients with persistent, recurrent, or metastatic cervical cancer who received chemotherapy with or without bevacizumab had longer progression-free and overall survival vs placebo-treated patients.